They have been able to harvest healthy stem cells - the building blocks of life - from a diseased pancreas and mature them into insulin-producing cells.
we can deliver twice-yearly lenacapavir for PrEP worldwide, for all those who want or need PrEP.” While the results are good news, the drug is expensive. The National Institutes of Health have ...
Lenacapavir, a twice-yearly injectable antiretroviral, reduced the risk of HIV infection by 96% in a large study of gay and bisexual men and gender diverse people, according to a Gilead Sciences ...
Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in ...